Psych Pharm Flashcards
medication category for:
first generation- haloperidol
second generation- risperidone
antipsychotics
medication category for:
MAOIs
tricyclics, tetracyclics
SRIs or SRAs
SSRIs, SNRIs
atypical’s or NDRI’s
5HT1a agonist/5HT3 antagonist
SSRI/5HT1a partial agonist
antidepressants
medication category for:
lithium
anti-seizure drug- valproate
anxiolytics-antihistamine, anti-hypertensive, benzodiazepine
mood stabilizers
medication category for:
zolpidem
ramelteon
temazepam
suvorexant
ADHD meds
hypnotics
can neural circuits “learn” over time?
yes
over-stimulated circuits become dysregulated
- circuit activity breaks down resulting in dysfunction
- circuit dysfunciton is seen as symptoms
stimulate receptors
agonist
stimulate with ceiling & occupy receptor (which precludes other NT’s from attaching)
partial agonists
block agonist from receptor
antagonist
blocks agonists at receptor & reduce activity below baseline constitute activity
inverse agonist
psychiatric symptoms related to _______ _______
related to neural circuits
circuit contains ________ and ________
neurotransmitters and receptors
_______ activity drives symptoms
receptor
modulate receptor activity with ______
drugs
excess stimulation of the portions of the CNS that control motor function that are outside of the pyramidal tract
group of syndromes w/ signs of abnormal motor movement result from D2 antagonism (bradykinesia, incoordination, spasms)
extrapyramidal syndrome (EPS)
“late appearing dyskinesias”
a form of EPS
primarily orofacial dyskinesia
D2 receptor blockade
may be permanent
tardive dyskinesia
excess level of 5HT producing akithesia, muscle twitching, hyper-reflexia, penile erection, seizures, coma
serotonin syndrome
excess antagonism of D2 receptor producing muscle rigidity, fever, unstable BP, myoglobinemia
may be fatal
an extreme manifestation
genetically determined hypersensitivity to anesthetic agents resulting in severe hyperthermia, accelerated muscle metabolism, metabolic acidosis
malignant hypertension
syndrome including:
at a minimum, hallucinations, delusions
frequently also disorganized speech and behavior, gross distortions of reality testing
psychosis
drug class for haloperidol
first generation antipsychotic
indications for haloperidol
psychotic symptoms
(defining & associative symptoms)
MoA for haloperidol
D2 antagonist
inhibits alpha1, but not M1, H1
drug class for risperidone
SGA
atypical antipsychotic
indications for risperidone
psychosis (positive & negative symptoms)
mania
MoA for risperidone
5HT and DA antagonist
mild alpha1, alpha2, H1 antagonism
drug class for quetiapine
SGA
atypical antipsychotic
D2 & 5HT antagonist
indications for quetiapine
bipolar disorder
schizophrenia
adjunct in MDD
off-label: GAD, OCD, PTSD
MoA for quetiapine
D2 and 5HT2 antagonism
high affinity for M1 muscarinic receptors
drug class for lurasidone
SGA
atypical antipsychotic
D2, 5HT2, 5HT7 antagonist
5HT1a partial agonist
indications for lurasidone
schizophrenia
bipolar 1 disorder
MoA for lurasidone
D2, 5HT2, 5HT7 antagonist
5HT1 partial agonist
drug class for ziprasidone
SGA
indications for ziprasidone
bipolar disorder
schizophrenia
acute agitation in schizophrenia
MoA for ziprasidone
D2, 5HT2a, 5HT1d antagonist
5HT1a agonist
moderate 5HT and NE reuptake inhibition
what do we want to rule out before treating what looks like depression?
mania
what is the black box warning for all young adults for all antidepressants?
suicide risk
treatment goals:
what is the success rate w/ antidepressants?
60-80%
after starting antidepressants, how long does it take to see improvements in emotions?
2-4 weeks
how long does it take to see the full impact of antidepressants?
6-8 weeks
drug class for phenelzine
monoamine oxidase inhibitor (MAOI)
indications for phenelzine
depression refractory to other Rx, ECT
MoA for phenelzine
inhibition of MAO producing increased NE, DA, 5HT
drug class for nortriptyline
tricyclic antidepressant
indications for nortriptyline
depressive disorders
off-label: chronic pain, anxiety, enuresis, ADHD
MoA for nortriptyline
inhibit SERT, NET
block 5HT2A receptors
drug class for mirtazapine
tetracyclic
alpha2 antagonist
indications for mirtazapine
depression
MoA for mirtazapine
antagonism of alpha2 receptors dishibits 5HT, NE release;
blocks NE negative feedback inhibits of NE, 5HT release
drug class for trazadone
SARIs
5HT2A, 5HT2C antagonist & reuptake inhibitors
indications for trazadone
MDD
insomnia (lower doses)
MoA for trazadone
antagonist of 5HT2A, 5HTC and inhibits reuptake serotonin via SERT, reduces number of 5HT receptors & increasing 5HT flow in neuron
drug class for fluoxetine
selective serotonin reuptake inhibitor (SSRI)
indications for fluoxetine
MDD
dysphoric disorder
anxiety
eating disorders
OCD
MoA for fluoxetine
inhibit reuptake serotonin via SERT reducint number 5HT receptors & increasing 5HT flow in neuron;
mild NRI, DRI, 5HT2C inhibition, CYP2D6 & 3A4 inhibition
drug class for sertraline
SSRI antidepressant
indications for sertraline
MDD
PMDD
PD
PTSD
social anxiety disorder
OCD
MoA for sertraline
selectively inhibits SERT & increases 5HT level in synapse
drug class for citalopram
SSRI antidepressant
indications for citalopram
depression
MoA for citalopram
selectively inhibits SERT & mild antihistamine (H1) activity
drug class for venlafaxine
serotonin & NE reuptake inhibitors (SNERIs)
indications for venlafaxine
MDD
GAD
SAD
panic disorder
off-label: pain, OCD, hot flashes
MoA for venlafaxine
inhibits SERT at lower doses, NET at high doses
drug class for duloxetine
SNERI antidepressant
indications for duloxetine
MDD
DPNP
fibromyalgia
GAD
chronic MSK pain
MoA for duloxetine
elevates levels of 5HT, NE, and DA
elevates DA levels in PFC
drug class for buproprion
NE, DA reuptake transporter inhibitors (NDRIs)
indications for buproprion
depression
smoking cessation
MoA for buproprion
NE, DA reuptake inhibition
drug class for vortioxetine
SSRI
indications for vortioxetine
MDD
MoA for vortioxetine
inhibits SERT, partial agonist at 5HT1a and 5HT3 antagonist
drug class for vilazodone
SPARI (serotonin partial agonist reuptake inhibitor)
indications for vilazodone
MDD
MoA for vilazodone
inhibits SERT with elevatio of 5HT levels & has 5HT1a partial agonist activity
drug class for lithium
mood stabilizer
indications for lithium
bipolar disorder
mania
possible SE/ADR of lithium
diabetes insipidus
drug class for valproate
anti-seizure med
mood stabilizer
indications for valproate
seizure disorder
mania
aggression
MoA for valproate
increase GABA concentration
drug class for hydroxyzine
antihistamine (H1)
anxiolytic
indications for hydroxyzine
anxiety, pruritis, sedation
MoA for hydroxyzine
inhibits H1 receptors
drug class for propanolol
beta blocker
anxiolytic
indications for propanolol
HTN
anxiety
tremor
hyperthyroidism
MoA for propanolol
nonselective beta blocker
drug class for diazepam
benzodiazepine anxiolytic
indications for diazepam
bridge therapy in anxiety disorders
sedative, status epilepticus, alcohol withdrawal
MoA for diazepam
binds to & stabilizes BZD receptor on post-synaptic GABA neuron in limbic system & reticular formation enhancing GABA impact
drug class for oxazepam
benzodiazepine anxiolytic
indications for oxazepam
bridge therapy in anxiety disorders
sedative, alcohol withdrawal
MoA for oxazepam
binds to & stabilizes BZD receptor on post-synaptic GABA neuron in limbic system & reticular formation enhancing GABA
drug class for buspirone
miscellaneous anxiolytic
indications for buspirone
anxiety
MoA for buspirone
5HT1A partial agonist modulates 5HT levels
drug class for zolpidem
non-benzodiaepine hypnotic
indications for zolpidem
short-term treatment insomnia
MoA for zolpidem
selective agonist for alpha1 subunit of BZD receptor of GABA receptor complex -> increase GABA impact
drug class for esopiclone
hypnotic, nonbenzodiazepine
indications for esopiclone
insomnia
drug class for zaleplon
hypnotic
nonbenzodiazepine
indications for zaleplon
short-term treatment insomnia
drug class for ramelteon
hypnotic
miscellaneous
indications for ramelteon
insomnia
drug class for temazepam
hypnotic
benzodiazepine
indications for temazepam
short-term treatment of insomnia
drug class for suvorexant
hypnotic
orexin receptor antagonist
indications for suvorexant
insomnia
MoA for suvorexant
blockes wake-promoting orexin-A and orexin-B to receptors OX1R and OXR2 which suppresses wake drive
what are the 2 ADHD meds?
methylphenidate
atomexetine
drug class for methylphenidate
CNS stimulant
indications for methylphenidate
symptomatic treatment of ADHD, narcolepsy
off-label: depression in terminally ill
drug class for atomexetine
SNRI
indications for atomoxetine
ADHD
drug class for acamprosate
GABA agonist/glutamate antagonist
indications for acamprosate
maintenance of alcohol abstinence
drug class for disulfram
aldehyde dehydrogenase inhibitor
indications for disulfram
maintenance of alcohol abuse
drug class for naltrexone
opioid antagonist
indications for naltrexone
maintenance of alcohol or opioid absitnence
off-label: cholestatic pruritis
drug class for methadone
opioid analgesic
indications for methadone
low doses- analgesia
treatment of opioid addiction
drug class for buprenorphine
opioid partial agonist
indications for buprenorphine
analgesia
opioid withdrawal
dependence
drug class for naloxone
opioid antagonist
indications for naloxone
opioid overdose
drug class for buprenorphine & naloxone
opioid partial agonist & opioid antagonist
indications for buprenorphine & naloxone
maintenance herapy for opioid dependence
*not for induction of abstinence